Skip to main content

Table 3 Reticulocyte Counts Increments and Percentage Reduction of Serum Iron during the study

From: Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

 

Formulation A N= 17

Formulation B N= 16

p A vs. B

Reticulocyte counts

Increments (×109/L) (p for paired test) significance level p = 0.010

 

T48 -T0

2.5 ± 4.2 (0.109)

2.4 ± 3.4 (0.028)

0.694

T72 -T0

2.4 ± 3.4 (0.078)

2.5 ± 3.7 (0.011)

0.520

T120 -T0

2.8 ± 2.9 (0.001)

2.9 ± 2.8 (0.002)

0.986

T144 -T0

3.2 ± 2.8 (<0.001)

2.8 ± 2.7 (0.002)

0.552

T216-T0

2.8 ± 2.2 (< 0.001)

2.5 ± 2.4 (0.001)

0.407

Serum iron

% Reduction (p for paired test) significance level: p = 0.025

 

T120 -T0

42.7 ± 20.5 (0.001)

35.7 ± 17.1 (0.001)

0.205

T216-T0

37.0 ± 21.4 (0.050)

17.3 ± 19.4 (0.541)

0.805

  1. Data are reported as mean ± standard deviation.
  2. Paired tests vs. baseline were done by the Wilcoxon's test and comparison between formulations at each time by the Mann-Whitney's U test.